Vyome Holdings, Inc (HIND): R&D Expense
$588.3K
Year ended 2025-12-31
-38.6%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $588.3K | +106.1% | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $285.4K | -87.7% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $2.31M | -8.8% | 2025-04-04, From 2023-01-01 |
| 2022-12-31 | $2.54M | +7.1% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $2.37M | n/c | 2023-04-17, From 2021-01-01 |
| 2020-12-31 | $3.50M | n/c | 2022-04-08, From 2020-01-01 |
| 2019-12-31 | $6.89M | -35.6% | 2021-03-12, From 2019-01-01 |
| 2018-12-31 | $10.70M | +0.5% | 2020-02-27, From 2018-01-01 |
| 2017-12-31 | $10.65M | +7.9% | 2019-02-22, From 2017-01-01 |
| 2016-12-31 | $9.87M | -23.9% | 2018-03-05, From 2016-01-01 |
| 2015-12-31 | $12.98M | +125.0% | 2018-03-05, From 2015-01-01 |
| 2014-12-31 | $5.77M | n/a | 2017-02-23, From 2014-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | 2025-12-31 | $588.3K | +106.1% |
| Allarity Therapeutics, Inc. (ALLR) | 2025-12-31 | $6.60M | +8.3% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | $121.1K | -32.5% |
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | $6.69M | +16.3% |
| Medicinova Inc (MNOV) | 2025-12-31 | $6.70M | -1.5% |
| Scienture Holdings, Inc. (SCNX) | 2025-12-31 | $1.96M | -12.5% |
| Regen BioPharma Inc (RGBP) | 2025-09-30 | $11.7K | -92.4% |
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | $17.77M | -15.1% |
Compare HIND, ALLR, PVCT, ABVC side by side · Screen every company in Pharmaceutical Preparations ↗